Literature DB >> 7488225

Piracetam-induced changes to membrane physical properties. A combined approach by 31P nuclear magnetic resonance and conformational analysis.

J Peuvot1, A Schanck, M Deleers, R Brasseur.   

Abstract

Piracetam, Nootropil (2-oxo-1-pyrrolidine acetamide), is a drug promoting erythrocyte deformability. To establish the mode of action of this compound, we have investigated its influence on the organization of model phospholipid membranes. 31P NMR data show that the drug induces a structural modification in liposomes made of phosphatidylcholine and phosphatidylethanolamine. Our conformational analysis results have allowed the interpretation of the effect of piracetam on these model membranes: the specific interaction between the drug molecules and the phosphate headgroups induces a new organization of the lipids favouring formation of mobile drug-phospholipid complexes that exhibit an isotropic-type signal in the 31P NMR spectra.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7488225     DOI: 10.1016/0006-2952(95)00225-o

Source DB:  PubMed          Journal:  Biochem Pharmacol        ISSN: 0006-2952            Impact factor:   5.858


  9 in total

1.  Progressive Myoclonic Epilepsies.

Authors:  Basim M. Uthman; Andreas Reichl
Journal:  Curr Treat Options Neurol       Date:  2002-01       Impact factor: 3.598

2.  Piracetam improves mitochondrial dysfunction following oxidative stress.

Authors:  Uta Keil; Isabel Scherping; Susanne Hauptmann; Katin Schuessel; Anne Eckert; Walter E Müller
Journal:  Br J Pharmacol       Date:  2006-01       Impact factor: 8.739

3.  Piracetam relieves symptoms in progressive myoclonus epilepsy: a multicentre, randomised, double blind, crossover study comparing the efficacy and safety of three dosages of oral piracetam with placebo.

Authors:  M Koskiniemi; B Van Vleymen; L Hakamies; S Lamusuo; J Taalas
Journal:  J Neurol Neurosurg Psychiatry       Date:  1998-03       Impact factor: 10.154

4.  Improved mitochondrial function in brain aging and Alzheimer disease - the new mechanism of action of the old metabolic enhancer piracetam.

Authors:  Kristina Leuner; Christopher Kurz; Giorgio Guidetti; Jean-Marc Orgogozo; Walter E Müller
Journal:  Front Neurosci       Date:  2010-09-07       Impact factor: 4.677

5.  Piracetam prevents scopolamine-induced memory impairment and decrease of NTPDase, 5'-nucleotidase and adenosine deaminase activities.

Authors:  Patricia C Marisco; Fabiano B Carvalho; Michelle M Rosa; Bruna A Girardi; Jessié M Gutierres; Jeandre A S Jaques; Ana P S Salla; Víctor C Pimentel; Maria Rosa C Schetinger; Daniela B R Leal; Carlos F Mello; Maribel A Rubin
Journal:  Neurochem Res       Date:  2013-05-16       Impact factor: 3.996

6.  Treatment duration affects cytoprotective efficacy of positive allosteric modulation of α7 nAChRs after focal ischemia in rats.

Authors:  Nikhil Gaidhani; Victor V Uteshev
Journal:  Pharmacol Res       Date:  2018-09-08       Impact factor: 7.658

7.  Evaluation of the bioactivity of novel spiroisoxazoline typecompounds against normal and cancer cell lines.

Authors:  Nigar Najim; Yaser Bathich; Mazatulikhma Mat Zain; Ahmad Sazali Hamzah; Zurina Shaameri
Journal:  Molecules       Date:  2010-12-17       Impact factor: 4.411

8.  Protective effect of co-administration of caffeine and piracetam on scopolamine-induced amnesia in Wistar rats.

Authors:  Subhash Chaturvedi; Aditya Ganeshpurkar; Abhishek Shrivastava; Nazneen Dubey
Journal:  Curr Res Pharmacol Drug Discov       Date:  2021-09-08

9.  Postseizure aphasia in Wernicke's encephalopathy: a case report and review of literature.

Authors:  Sandhya Devaraj; Sara A Muralles; Chandler E Gill; Edwin Meresh
Journal:  Neuropsychiatr Dis Treat       Date:  2018-10-08       Impact factor: 2.570

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.